Literature DB >> 6570085

Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.

M E Gombert, T M Aulicino.   

Abstract

The susceptibility of 10 multiply antibiotic-resistant strains of Streptococcus pneumoniae to several quinoline antibiotics and to coumermycin, novobiocin, and penicillin was determined. The MIC of penicillin for all test isolates was greater than or equal to 4 micrograms/ml. Ciprofloxacin was the most active quinoline derivative tested, followed by norfloxacin. These isolates of S. pneumoniae were not inhibited by the remaining quinolines at achievable concentrations in serum. Coumermycin and ciprofloxacin were the most active antibiotics tested in this study.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6570085      PMCID: PMC180054          DOI: 10.1128/AAC.26.6.933

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Emergence of multiply resistant pneumococci.

Authors:  M R Jacobs; H J Koornhof; R M Robins-Browne; C M Stevenson; Z A Vermaak; I Freiman; G B Miller; M A Witcomb; M Isaäcson; J I Ward; R Austrian
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  Penicillin-binding proteins of multiply antibiotic-resistant South African strains of Streptococcus pneumoniae.

Authors:  S Zighelboim; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

4.  Susceptibility of multiply antibiotic-resistant pneumococci to the new beta-lactam drugs and rosaramicin.

Authors:  S H Landesman; M Cummings; A Gruarin; H Bernheimer
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

5.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

6.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

7.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 8.  Antibiotic-resistant Streptococcus pneumoniae: clinical and epidemiologic aspects.

Authors:  J Ward
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

9.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  9 in total
  12 in total

1.  LVIS553 transcriptional regulator specifically recognizes novobiocin as an effector molecule.

Authors:  Fernando A Pagliai; Christopher L Gardner; Santosh G Pande; Graciela L Lorca
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  In vitro activity of ciprofloxacin combined with azlocillin.

Authors:  J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 4.  World-wide development of antibiotic resistance in pneumococci.

Authors:  P C Appelbaum
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 5.  Inhibition of drug metabolism by quinolone antibiotics.

Authors:  D J Edwards; S K Bowles; C K Svensson; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 6.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

7.  Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.

Authors:  T Mazzulli; A E Simor; R Jaeger; S Fuller; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

8.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.